Prodotto da Moderna e denominato mFlusiva, ha dimostrato di essere fino al 27 per cento più efficace rispetto al vaccino antinfluenzale standard

The FDA has approved the nation’s first messenger RNA-based influenza vaccine, marking a significant development in the fight against the respiratory illness — and the end of a…

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.